Core Viewpoint - Haier Biomedical has received a report from Qindao Jiushi Investment Management Co., indicating that Jiushi Youxuan No. 1 Fund plans to increase its stake in the company by 15,897,909 shares, representing 5.00% of the total share capital, due to a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [1][2]. Group 1 - Jiushi Youxuan No. 1 Fund is currently the second-largest circulating shareholder of Yinkang Life, showcasing its strategic focus on the medical technology sector and recognition of Haier Biomedical's solid fundamentals and clear growth logic [2]. - Haier Biomedical, a leader in low-temperature storage equipment in the biomedical sector, achieved a net profit of 143 million yuan in the first half of 2025, with new industry revenue accounting for 47% of total revenue, driving performance growth [2]. - The company has established a collaborative development framework across four major industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, with significant market shares in various segments [2]. Group 2 - Haier Group, the actual controller of Haier Biomedical, has recently formed a comprehensive strategic partnership with Ant Group to promote the digital upgrade of healthcare services, positioning Haier Biomedical for new growth opportunities [3]. - The investment from Jiushi Youxuan No. 1 Fund is seen as a recognition of Haier Biomedical's technological barriers and growth potential, which may boost investor confidence and provide stronger momentum for the company's long-term development [3].